Clinical Trials Browser

Completed × Ependymoma × Bevacizumab × Clear all

NCT01295944 2025-08-05

Carboplatin and Bevacizumab for Recurrent Ependymoma

Phase 2 Completed

35 enrolled 17 charts

Brain Neoplasms, Ependymoma, Neoplasms, Neurologic Manifestations, Spinal Cord Neoplasms

NCT01125046 2021-01-22

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Phase 2 Completed

50 enrolled 13 charts

Brain Neoplasms, Ependymoma, Meningioma, Neurofibromatosis 1, Neuroma, Acoustic, Neurofibromatosis 2

NCT00883688 2020-08-26

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

Phase 2 Completed

24 enrolled 5 charts

Brain Neoplasms, Ependymoma, Neuroectodermal Tumors, Primitive, Glioma, Subependymal

NCT00352521 2014-07-22

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

Phase 2 Completed

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00492089 2014-05-09

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

Phase 2 Completed

11 enrolled 7 charts

Hemangiopericytoma, Malignant, Squamous Cell Carcinoma of Head and Neck, Astrocytoma, Brain Neoplasms, Ependymoma, Glioma, Meningioma, Neoplasms, Oligodendroglioma, Pinealoma, Radiation Injuries, Salivary Gland Neoplasms, Choroid Plexus Neoplasms, Esthesioneuroblastoma, Olfactory

NCT00463203 2011-06-29

Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy

Phase 2 Completed

Brain Neoplasms, Ependymoma, Glioma, Recurrence